Resultado fase2: Mal.
– 64%.

Joe, de palo en palo.

Y a esta que le pasado hoy?
Menuda subida..

Super,Framus mirad esta noticia para comprobar su veracidad,no se si el repor es de fiar, pero puede justificar las ultimas subidas??
http://www.insiderfinancial.com/threshold-pharmaceuticals-inc-nasdaqthld-making-a-comeback/114785/

Por eso la enorme discrepancia entre las estimaciones de los analistas y el report financiero real dado por la empresa.

Destello de un día, poco mas, a mi parecer.

Quise decir COMPRANDO,sorry

Ahora si seria el momento optimo de saber quien esta comparando,si son los duros o son los blandos.

http://finance.yahoo.com/news/threshold-pharmaceuticals-announces-presentation-webcast-120000217.html

http://investor.thresholdpharm.com/secfiling.cfm?filingid=1144204-16-76687&CIK=1183765
On January 21, 2016, Threshold Pharmaceuticals, Inc. (the “Company”) received a notice from the from the staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) that, for the previous 30 consecutive business days, the closing bid price for the Company’s common stock was below the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company will have 180 calendar days, or until July 19, 2016, to regain compliance with the Bid Price Rule. To regain compliance with the Bid Price Rule, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company regains compliance with the Bid Price Rule, Nasdaq will provide the Company with written confirmation and will close the matter.

If the Company does not regain compliance with the rule by July 19, 2016, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to meet, on the 180th day of the first compliance period, the continued listing requirement for market value of publicly held shares and all other applicable standards for initial listing on The NASDAQ Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is not eligible for a second compliance period, Nasdaq will notify the Company that its common stock will be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing.

On January 11, 2016, Threshold Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that an Independent Data Safety Monitoring Board (IDSMB) had completed an unplanned interim efficacy and safety analyses of unblinded data for the Company’s pivotal Phase 2 clinical trial of evofosfamide plus pemetrexed versus pemetrexed alone in patients with non-squamous non-small cell lung cancer. Based on the analyses, the IDSMB concluded that the trial is unlikely to reach its primary endpoint of improving overall survival with statistical significance and as a result, enrollment in this trial will be closed to further enrollment.

The Company also announced in the press release that Merck KGaA, Darmstadt, Germany, has agreed to key terms to license back all rights to the evofosfamide program to the Company and as such, both companies are currently engaged in negotiating final terms for the return of rights to evofosfamide.
http://investor.thresholdpharm.com/secfiling.cfm?filingID=1144204-16-74962&CIK=1183765

Gracias!!!!!

A mediados de año tiene resultados de fase 2 de pulmon. Por buscar un motivo para el brinco ahi puede haber uno.

Una pregunta Framus. Tu que te has empollado mucho esta farmacia en los últimos tiempos. Esta ya la ves en uci vegetativo ?? Opinas que una inversión a LARGO desde los niveles en los que está podría tener futuro? O más pinta de que este condenada a perderse en los suburbios?

Gracias!!!